KIROMIC BIOPHARMA INC (KRBP)       0.25  0 (-0.2%)

0.25  0 (-0.2%)

US4976341051 - Common Stock

KIROMIC BIOPHARMA INC0.25

NASDAQ:KRBP (12/6/2022, 7:00:03 PM)0 (-0.2%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-12 2022-08-12/amc Earnings (Next) 03-09 2023-03-09
Ins Owners 6.56% Inst Owners 1.68%
Market Cap 4.56M Shares 18.25M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts N/A
IPO 10-16 2020-10-16

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

KRBP Daily chart

Company Profile

Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. The company is headquartered in Houston, Texas and currently employs 59 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.

Company Info

KIROMIC BIOPHARMA INC

7707 Fannin St., Suite 140

Houston TEXAS 77054

P: 18329684888.0

CEO: Maurizio Chiriva-Internati

Employees: 59

Website: https://kiromic.com/

KRBP News

News Imagea month ago - SBWireNASDAQ:KRBP Long Term Investor Alert: Investigation over Possible Wrongdoing at Kiromic BioPharma, Inc.

San Diego, CA -- (SBWIRE) -- 11/09/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Kiromic BioPharma, Inc..

News Imagea month ago - Schubert Jonckheer & Kolbe LLPSHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial Prospects

/PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP)...

News Imagea month ago - Kiromic BioPharma, Inc.Kiromic BioPharma Arranges Up to $10 Million FinancingNews Image2 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

News Image2 months ago - Kiromic BioPharma, Inc.Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development StrategyNews Image2 months ago - The Klein Law FirmKRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP)...

KRBP Twits

Here you can normally see the latest stock twits on KRBP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example